Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma
- 1 April 2016
- journal article
- case report
- Published by Ovid Technologies (Wolters Kluwer Health) in Melanoma Research
- Vol. 26 (2), 202-204
- https://doi.org/10.1097/cmr.0000000000000232
Abstract
We report the occurrence of autoimmune hemolytic anemia in a patient receiving the anti-PD-1 monoclonal antibody, nivolumab, for metastatic melanoma in the presence of known red cell alloantibodies, despite having received prior ipilimumab without evidence of hemolysis. The patient had a history of multiple red cell alloantibodies and a positive direct antiglobulin test, identified at the time of a prior transfusion, which occurred before treatment with ipilimumab. The patient developed symptomatic warm autoimmune hemolytic anemia after four cycles of treatment with nivolumab. Clinical improvement was noted following cessation of the drug and treatment with corticosteroids. Given that there was no prior history of hemolysis, even during treatment with ipilimumab, we hypothesize that anti-PD-1 therapy disrupted peripheral tolerance, unmasking an underlying autoimmune predisposition.Keywords
This publication has 13 references indexed in Scilit:
- In VitroCharacterization of the Anti-PD-1 Antibody Nivolumab, BMS-936558, andIn VivoToxicology in Non-Human PrimatesCancer Immunology Research, 2014
- Serious haematological toxicity during and after ipilimumab treatment: a case seriesJournal of Medical Case Reports, 2014
- Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic MelanomaJournal of Immunotherapy, 2014
- Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced MelanomaJournal of Clinical Oncology, 2013
- PD-1 is a novel regulator of human B-cell activationInternational Immunology, 2012
- Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanomaCancer Immunology, Immunotherapy, 2008
- Red cell aplasia and autoimmune hemolytic anemia following immunosuppression with alemtuzumab, mycophenolate, and daclizumab in pancreas transplant recipients.Haematologica, 2007
- Severe Autoimmune Hemolytic Anemia Following Rituximab Therapy in a Patient with a Lymphoproliferative DisorderLeukemia & Lymphoma, 2003
- Immunological studies on PD-1 deficient mice: implication of PD-1 as a negative regulator for B cell responsesInternational Immunology, 1998
- Expression of the PD-1 antigen on the surface of stimulated mouse T and B lymphocytesInternational Immunology, 1996